menu
    • menu
    [{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"GB-0895","moa":"TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Generate Biomedicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Generate Biomedicines \/ Undisclosed"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series C Financing","leadProduct":"GB-0669","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Generate Biomedicines","amount2":0.27000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.27000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Generate Biomedicines \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Generate Biomedicines \/ Amgen Inc"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GB-0669","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Generate Biomedicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Generate Biomedicines \/ Undisclosed"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GB-7624","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generate Biomedicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Generate Biomedicines \/ Undisclosed"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Generate Biomedicines","amount2":1.8999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.8999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Generate Biomedicines \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Generate Biomedicines \/ Amgen Inc"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generate Biomedicines \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Generate Biomedicines \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Generate Biomedicines","amount2":1.0700000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.0700000000000001,"dosageForm":"Undisclosed","sponsorNew":"Generate Biomedicines \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Generate Biomedicines \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generate Biomedicines \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Generate Biomedicines \/ The University of Texas MD Anderson Cancer Center"}]

    Find Clinical Drug Pipeline Developments & Deals by Generate Biomedicines

    Menu

    Generate Biomedicines

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GB-0895

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate GB-0895 in Adults with Mild to Moderate Asthma or COPD

                            Details : GB-0895 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Asthma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 12, 2025

                            Lead Product(s) : GB-0895

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GB-0669

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Investigate Safety, Tolerability & PK of GB-0669 in Healthy Adults

                            Details : GB-0669 is a Other Large Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 03, 2025

                            Lead Product(s) : GB-0669

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GB-7624

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants

                            Details : GB-7624 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 10, 2025

                            Lead Product(s) : GB-7624

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,065.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Novartis Inks $1B-plus Biobucks Deal with Flagship's Generate

                            Details : The collaboration leverages Generate’s proprietary generative AI platform to create potentially first- and best-in-class molecules through AI-based optimization and de novo generation.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $65.0 million

                            September 24, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,065.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Roswell Park Comprehensive Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Generate:Biomedicines and Roswell Park Comprehensive Cancer Center Enter into a Collaboration Agreement to Acc...

                            Details : The collaboration aims to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 01, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Roswell Park Comprehensive Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GB-0669

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Amgen Inc

                            Deal Size : $273.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Generate:Biomedicines Announces Close of $273M Series C Financing to Advance its Generative AI Pipeline of Pre...

                            Details : The financing will be used to advance company's Generative AI pipeline of preclinical and clinical protein therapeutics, including GB-0669, a monoclonal antibody targeting a highly conserved region of the spike protein, in SARS-CoV-2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 14, 2023

                            Lead Product(s) : GB-0669

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Amgen Inc

                            Deal Size : $273.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Generate:Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement to Accelerate Novel...

                            Details : The collaboration aims to jointly discover and co-develop protein therapeutics for up to 5 oncology targets in advanced cancers, including small-cell and NSCLC. The agreement combines Generate:Biomedicines’ The Generate Platform with MD Anderson’s cl...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 27, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed

                            Generate Biomedicines

                            U.S.A arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Amgen Inc

                            Deal Size : $1,900.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement

                            Details : Generate Biomedicine's integrated in silico design and wet lab capabilities combined with Amgen to harness its machine-learning-enabled technology to discover and develop protein therapeutics for five clinical targets across a range of therapeutic areas ...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $50.0 million

                            January 06, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Amgen Inc

                            Deal Size : $1,900.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth